Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Raymond ...

Insulet (NASDAQ:PODD – Get Free Report) had its price objective boosted by analysts at Piper Sandler from $285.00 to $310.00 ...

Q4 2024 Management View CEO Jim Hollingshead highlighted the company’s achievement of $2.1 billion in revenue for 2024, marking a doubling of revenue in just three years. He emphasized the strong ...

JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 ...

The company produces and sells Omnipod, an automated insulin delivery device, which works without the need for external ...

Insulet Corp (PODD) surpasses $2 billion in revenue with strong Omnipod 5 demand, while navigating pricing headwinds and ...

Insulet (Nasdaq:PODD) shares dipped after hours today on fourth-quarter results that came in ahead of the consensus forecast.

Insulet Corporation PODD reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.15, down significantly 17.8% ...

For the year ending December 31, 2025, the Company expects revenue growth of 16% to 20%. Revenue growth ranges by product line are: Total ...

Reports Q4 revenue $597.5M, consensus $582.02M. “We concluded an incredible year with a very strong fourth quarter, achieving significant ...